Viatris (VTRS) Operating Expenses (2019 - 2026)
Viatris' (VTRS) quarterly Operating Expenses came in at $1.2 billion in Q1 2026, down 69.41% year-on-year from $4.0 billion in Q1 2025, and down 7.74% quarter-over-quarter from $1.3 billion in Q4 2025.
Viatris (VTRS) Operating Expenses (2019 - 2026) Analysis & Trends
Viatris' Operating Expenses history runs 8 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- On a quarterly basis, Operating Expenses fell 69.41% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $4.9 billion, a 41.72% decrease from a year earlier, with the FY2025 full-year figure at $7.7 billion, up 36.75% from the prior year.
- Operating Expenses declined to $1.2 billion in Q1 2026 per VTRS's latest filing, from $1.3 billion in the prior quarter.
- Across five years, Operating Expenses topped out at $4.0 billion in Q1 2025 and bottomed at $1.1 billion in Q1 2022.
- The 5-year median for Operating Expenses is $1.2 billion (2023), against an average of $1.5 billion.
- Across the five-year window, Operating Expenses jumped 211.01% in 2025 and slumped 69.41% in 2026, its largest moves.
- Year by year, Operating Expenses stood at $1.5 billion in 2022, then jumped by 39.01% to $2.1 billion in 2023, then sank by 31.99% to $1.4 billion in 2024, then dropped by 3.89% to $1.3 billion in 2025, then declined by 7.74% to $1.2 billion in 2026.
- Per Business Quant, the three latest VTRS Operating Expenses figures stand at $1.2 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.00 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 788.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 12.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 455.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.24 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 621.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 494.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 50.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.24 Bn |
| Dec 31, 2025 | 1.34 Bn |
| Sep 30, 2025 | 1.19 Bn |
| Jun 30, 2025 | 1.10 Bn |
| Mar 31, 2025 | 4.04 Bn |
| Dec 31, 2024 | 1.39 Bn |
| Sep 30, 2024 | 1.23 Bn |
| Jun 30, 2024 | 1.69 Bn |
| Mar 31, 2024 | 1.30 Bn |
| Dec 31, 2023 | 2.05 Bn |
| Sep 30, 2023 | 1.24 Bn |
| Jun 30, 2023 | 1.24 Bn |
| Mar 31, 2023 | 1.14 Bn |
| Dec 31, 2022 | 1.48 Bn |
| Sep 30, 2022 | 1.19 Bn |
| Jun 30, 2022 | 1.15 Bn |
| Mar 31, 2022 | 1.06 Bn |
| Dec 31, 2021 | 1.62 Bn |
| Sep 30, 2021 | 1.22 Bn |
| Jun 30, 2021 | 1.38 Bn |